Please login to the form below
roxadustat
This page shows the latest roxadustat news and features for those working in and with pharma, biotech and healthcare.
CHMP recommends eight new medicines for EU approval
Finally, the CHMP has adopted positive opinions for Astellas and FibroGen’s Evrenzo (Roxadustat) for the treatment of anaemia symptoms in chronic kidney disease patients.
Latest news
-
Astellas files new application for expanded use of roxadustat in Japan
Astellas has set its sights on extending the use of roxadustat into Japan, for the treatment of anaemia associated with chronic kidney disease (CKD) in non-dialysis patients. . ... Together with partner FibroGen, Astellas has submitted a supplemental
-
GSK files anaemia drug daprodustat in Japan, its first market
Another oral HIF-PHI drug – AstraZeneca and FibroGen’s roxadustat– has already been approved in China for CKD anaemia.Additional competition could come from Akebia, which has a drug in the ... Astellas Pharma meanwhile has rights to roxadustat in
-
AZ preps new roxadustat filings, though data foxes investors
Comes with increased blood pressure warning label. AstraZeneca and FibroGen say they are preparing a US filing of roxadustat for anaemia in chronic kidney disease after reporting cardiovascular outcomes data from ... There is a significant unmet medical
-
First-line ovarian approval cements AZ’s Lynparza lead
And in another positive development, AZ also announced today that two additional phase 3 trials of its just-approved drug for anaemia in chronic kidney disease patients – roxadustat – backed the efficacy
-
China first market to approve AZ’s kidney drug roxadustat
Roxadustat was compared to treatment with epoetin alfa over 26 weeks, matching the ESA’s efficacy in achieving a significant increase in haemoglobin levels. ... AZ and FibroGen have rights to roxadustat in the US, China and other world markets, while
Astellas files new application for expanded use of roxadustat in Japan
GSK files anaemia drug daprodustat in Japan, its first market
AZ preps new roxadustat filings, though data foxes investors
First-line ovarian approval cements AZ’s Lynparza lead
China first market to approve AZ’s kidney drug roxadustat
More from news
Approximately 2 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
The sales forecast for Zolgensma is $2.09bn. Roxadustat, from AstraZeneca, FibroGen and Astellas, targets anaemia in chronic kidney disease (CKD).
-
China: AstraZeneca’s new engine for growth and innovation
Roxadustat is under accelerated review and, if approved, would also be the first locally- developed medicine to hit the Chinese market even before Europe and the US,” says Mallon. ... Finally, a data readout for roxadustat is expected by the end of 2018
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
China: AstraZeneca’s new engine for growth and innovation
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
New hires at FibroGen, Saniona and Turbine
I am energised to join a company with such an innovative pipeline, as well as the first-in-class asset roxadustat, which has the potential to change the treatment paradigm in
New hires at FibroGen, Saniona and Turbine
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital account director
-
Competitive
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
No results were found
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
